Savara (SVRA) Liabilities and Shareholders Equity (2010 - 2026)
Savara's (SVRA) quarterly Liabilities and Shareholders Equity came in at $221.6 million in Q1 2026, up 17.08% year-on-year from $189.3 million in Q1 2025, and down 12.54% on a QoQ basis from $253.4 million in Q4 2025.
Savara (SVRA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $221.6 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 17.08% year-over-year to $221.6 million in Q1 2026; TTM through Mar 2026 was $779.8 million, a 0.12% change from a year earlier, with the FY2025 full-year figure at $253.4 million, up 19.05% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $221.6 million, down from $253.4 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for SVRA reached as high as $253.4 million in Q4 2025 and fell as low as $119.8 million in Q2 2023.
- Historically, Liabilities and Shareholders Equity has averaged $172.8 million across 5 years, with a median of $163.8 million in 2025.
- Across the five-year window, Liabilities and Shareholders Equity soared 31.17% in 2024 and plunged 40.99% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $139.8 million in 2022, then gained by 27.03% to $177.6 million in 2023, then rose by 19.89% to $212.9 million in 2024, then rose by 19.05% to $253.4 million in 2025, then fell by 12.54% to $221.6 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $221.6 million in Q1 2026, $253.4 million in Q4 2025, and $140.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 221.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.65 Mn |
| Dec 31, 2025 | 253.44 Mn |
| Sep 30, 2025 | 140.92 Mn |
| Jun 30, 2025 | 163.77 Mn |
| Mar 31, 2025 | 189.32 Mn |
| Dec 31, 2024 | 212.88 Mn |
| Sep 30, 2024 | 238.82 Mn |
| Jun 30, 2024 | 139.67 Mn |
| Mar 31, 2024 | 158.30 Mn |
| Dec 31, 2023 | 177.56 Mn |
| Sep 30, 2023 | 182.07 Mn |
| Jun 30, 2023 | 119.83 Mn |
| Mar 31, 2023 | 129.36 Mn |
| Dec 31, 2022 | 139.78 Mn |
| Sep 30, 2022 | 147.76 Mn |
| Jun 30, 2022 | 156.78 Mn |
| Mar 31, 2022 | 166.21 Mn |
| Dec 31, 2021 | 176.60 Mn |
| Sep 30, 2021 | 187.27 Mn |
| Jun 30, 2021 | 196.43 Mn |